SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a biopharmaceutical company, is focused on developing and commercializing innovative therapeutics designed to treat life-threatening diseases. The company’s strategy is to in-license late-stage clinical products, and then develop them for commercialization throughout the world. SciClone simultaneously strives to increase revenues and important cash flow to fund the expansion of its business as well as the development of a worldwide product portfolio. For further information, visit the Company’s web site at www.sciclone.com.
- 17 years ago
QualityStocks
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Signs MOU to Advance Quantum Computing in South Korea
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, announced…
-
QualityStocksNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) to Deploy Fingerprint Drug Testing System Across MWS Sites in Australia
Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a leading Australian waste…
-
SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Among Early Adopters of Bitcoin Treasury Strategies Amid Growing Trend
SolarBank Corporation joins a group of 61 public companies adopting bitcoin treasury strategies. The company…